

CENTER FOR BIOTECHNOLOGY ANNOUNCES ANNUAL APPLIED RESEARCH AND DEVELOPMENT AWARDS

Awards support innovative research collaborations between academic faculty and regional bioscience companies

Stony Brook, NY - July 10, 2023 - <u>The Center for Biotechnology at Stony Brook University</u> (CFB) has announced the recipients of the 2023-2024 <u>Applied Research & Development (ARaD)</u> awards. The ARaD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.

The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

The CFB is supporting the project, "Wearable Haptic Device for Catheter Based Cardiac Procedures" that is being developed by HapticHeart Solutions. The company is collaborating with Dr. Wei Lin of the Department of Biomedical Engineering to upgrade the haptic handle of their current prototype to a sleek wearable device for a better experience and reduced cost. The technology has the potential to revolutionize the \$14B cardiac catheterization market.

Additionally, the CFB will support the project entitled "Development of a Structural Model and Enzyme-Inhibitor Interactions for a Novel Cancer Target" by Lime Therapeutics, a startup spun out of Memorial Sloan Kettering Cancer Center, in collaboration with Dr. Ivet Bahar, who serves as the Louis and Beatrice Laufer Chair and Director Laufer Center for Physical & Quantitative Biology within the Department of Biochemistry and Cell Biology at Stony Brook University. The goal of this project is to leverage the computational and molecular dynamics capabilities of Dr. Bahar's lab to achieve three specific aims related to optimizing the company's lead compound.

"Collaboration with New York State Companies has been a cornerstone of the Center for Biotechnology's mission since our inception nearly four decades ago," said Diane Fabel, Director of Operations for the Center for Biotechnology. "The projects supported by this year's Applied Research and Development showcase the innovative science happening all around us both in our academic institutions and bioscience companies and the Center for Biotechnology is excited to be an engine promoting interactions between the two."

The ARaD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies to have a positive impact on human health and society.

2023-2024 Applied Research and Development Awards

"Wearable Haptic Device for Catheter Based Cardiac Procedures" HapticHeart Solutions, Inc. & Dr. Wei Lin, Associate Professor, Biomedical Engineering, Stony Brook University

"Development of a Structural Model and Enzyme-Inhibitor Interactions for a Novel Cancer Target" Lime Therapeutics & Dr. Ivet Bahar, Louis and Beatrice Laufer Chair and Director Laufer Center for Physical & Quantitative Biology, Biochemistry and Cell Biology, Stony Brook University.

Contact: Kate Hutchinson Assistant Director, Outreach and Programs <u>kate.hutchinson@stonybrook.edu</u>

###

About the Center for Biotechnology at Stony Brook University

Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The Center for Biotechnology serves as an important catalyst in the development of new biomedical technology and emerging companies in New York State.

Through groundbreaking initiatives, the CFB supports technology commercialization and company formation by bridging the gap between discovery and commercial success and training the next generation of biomedical leaders. The Center for Biotechnology also supports New York's biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the state. The CFB has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others, as well as supported the formation or development of dozens of emerging bioscience companies.